Blood Pressure Targets in Older and Frail Adults

Definition and Clinical Context

Blood pressure management in older adults must account for chronological age, biological age, frailty, multimorbidity, cognitive status, functional capacity, orthostatic symptoms, and treatment burden. Although older adults are often defined chronologically, age thresholds are intrinsically arbitrary. A fit 75-year-old may be able to follow a treatment strategy used in younger adults, whereas a markedly frail 65-year-old may require the more cautious approach generally applied to older patients.

Frailty is characterized by reduced physiological reserve and increased vulnerability to adverse outcomes. It is dynamic and may improve or worsen with illness, treatment, or other interventions. Frailty commonly overlaps with multimorbidity and is frequent in patients with cardiovascular disease, including heart failure and ischaemic heart disease.

Ageing is associated with progressive increases in systolic blood pressure (SBP), while diastolic blood pressure (DBP) rises less steeply and may remain stable or decline later in life. Consequently, isolated systolic hypertension and widening pulse pressure are common in later life. These changes contribute to the complexity of defining an appropriate treatment target, particularly when a lower DBP, orthostatic hypotension, or impaired autonomic compensation limits tolerability.

Evidence Base and Its Limitations

Few adults aged 85 years or older have been included in randomized controlled trials. Moreover, trial participants who were described as frail generally had no more than mild frailty, limiting the applicability of trial findings to people with substantial functional impairment, multimorbidity, or limited life expectancy.

Available randomized evidence has not demonstrated that frailty weakens the cardiovascular benefits of blood-pressure lowering among the frailer participants enrolled in trials. In contrast, observational studies have sometimes suggested that lower blood pressure may be harmful in significantly frail patients, especially when baseline blood pressure is not markedly elevated. These apparent J-shaped associations are considered unreliable for guiding treatment because of potential confounding, reverse causality, and the association of arterial stiffness with both low DBP and increased mortality.

Older adults have a higher absolute cardiovascular risk than younger adults. Thus, although a smaller number of older patients may need treatment to prevent one adverse cardiovascular outcome, the potential benefit for an individual patient may remain substantial. At the same time, adverse effects such as hypotension, syncope, falls, and functional deterioration may have greater consequences in frail patients.

Clinical Assessment

Frailty and Functional Status

Treatment decisions should not be based on age alone. Assessment should include:

• Degree of frailty, preferably using validated clinical tests

• Ability to perform activities of daily living

• Cognitive status

• Risk of falls

• Symptoms or history suggesting orthostatic hypotension

• Multimorbidity

• Polypharmacy and overall therapeutic burden

• Life expectancy

• Patient priorities and preferences

Patients who are fit and independent generally benefit from guideline-directed blood-pressure treatment similar to that used in younger adults, provided it is tolerated. Patients with functional loss but preserved independence require a more detailed geriatric assessment. Where functional impairment is accompanied by inability to perform activities of daily living, treatment goals should be individualized and discontinuation of medication may become appropriate.

Frailty is potentially reversible. Management should therefore include consideration of treatable contributors, such as underlying comorbidities, supervised muscle-strengthening physiotherapy, exercise, and coordination and balance training.

Orthostatic Blood Pressure Measurement

Before starting or intensifying blood-pressure treatment, orthostatic hypotension should be assessed. The recommended procedure is to have the patient seated or supine for 5 minutes, followed by blood-pressure measurement 1 and/or 3 minutes after standing.

Orthostatic symptoms are particularly important in frail older adults because hypotension, syncope, and falls may outweigh the anticipated cardiovascular benefit of more intensive treatment. In patients with supine hypertension and orthostatic hypotension, non-pharmacological measures should be pursued first, and drugs that worsen orthostatic hypotension should be replaced where possible rather than simply reducing treatment intensity.

Blood Pressure Targets

General Treated Target

For most adults receiving antihypertensive drug treatment, the first treatment step is to reduce BP to:

• SBP <140 mmHg

• DBP <80 mmHg

The intended final SBP target for most adults is 120–129 mmHg when treatment is well tolerated. If this level cannot be achieved because of adverse effects, the recommended approach is to aim for the lowest pressure that is reasonably achievable and tolerated.

Treatment should generally reach the intended target within approximately 3 months.

Patients Aged 70 Years and Older

For patients aged 70 years or older, the ultimate SBP target is:

• <140 mmHg, with reduction toward 130 mmHg if tolerated

The evidence supporting lower targets is less robust in people older than 80 years and in those with frailty. Biological rather than chronological age should guide the practical interpretation of this recommendation.

Patients Aged 85 Years or Older

For patients aged 85 years or older, a more lenient and individualized target should be considered. A treated SBP below 140 mmHg may be appropriate, but the target should be adjusted according to tolerability, orthostatic symptoms, frailty, comorbidity, and patient priorities.

In patients with poorly tolerated treatment, clinically important frailty, or age of 85 years or older, a target of <140 mmHg or the lowest level reasonably achievable may be used rather than insisting on 120–129 mmHg.

Moderate-to-Severe Frailty

In moderate-to-severe frailty at any age, personalized and more lenient targets may be appropriate. A treated BP below 140/90 mmHg may be considered when a target of 120–129 mmHg is not tolerated or is inconsistent with the patient’s health priorities.

If frailty progresses and SBP falls, deprescribing may become necessary. There is no automatic requirement to discontinue antihypertensive treatment solely because a patient is very old or frail if treatment remains well tolerated, but treatment should be reviewed regularly.

Diastolic Blood Pressure

The preferred on-treatment DBP range is 70–79 mmHg. If SBP is already 120–129 mmHg but DBP remains ≥80 mmHg, further treatment to achieve DBP 70–79 mmHg may be considered, although this is not a universal requirement and must be balanced against tolerability and the risk of orthostatic symptoms.

Ambulatory and Home Monitoring Targets

No outcome-based trials have used ambulatory blood-pressure monitoring (ABPM) or home blood-pressure monitoring (HBPM) to guide treatment targets. Corresponding targets are therefore extrapolated from observational data.

A treated office SBP of approximately 130 mmHg is considered likely to correspond to:

• A 24-hour ambulatory SBP of approximately 125 mmHg

• A home SBP below 130 mmHg

Treatment Strategy

Shared Decision-Making

Patients should be informed about both the potential benefits and risks of initiating or intensifying treatment. In older and frail patients, shared decision-making should incorporate:

• Expected cardiovascular benefit

• Risk of hypotension, syncope, and falls

• Functional and cognitive status

• Competing comorbidities

• Life expectancy

• Medication burden

• Patient-defined priorities, including independence and quality of life

The objective is not simply numerical BP reduction but a balance between prevention of cardiovascular events and preservation of function, autonomy, and tolerability.

Initiation of Treatment

In patients aged 85 years or older or those with moderate-to-severe frailty, treatment should generally be initiated cautiously, with lower doses, slower titration, and closer monitoring. Monotherapy is preferred in most such patients unless BP is very high.

A long-acting dihydropyridine calcium-channel blocker may be used initially. An angiotensin-converting enzyme inhibitor may also be used, or an angiotensin receptor blocker if an ACE inhibitor is contraindicated. If additional therapy is required, a low-dose thiazide or thiazide-like diuretic may be added if tolerated.

Low-dose diuretic therapy may be unsuitable in the presence of:

• Gout

• Orthostatic hypotension

• Disturbed micturition

• Micturition syncope

Combination Therapy

In most very old or frail patients, initiation with combination treatment is not advised unless BP is substantially elevated. A strategy of low-dose double therapy followed, if necessary, by triple therapy can be used in other patients, with careful monitoring of tolerance before dose escalation.

Once an effective combination has been established, a single-pill combination may improve adherence. However, the composition and doses must remain appropriate as frailty, renal function, comorbidities, and concurrent prescriptions evolve.

Drug Classes Requiring Particular Caution

Beta-blockers are generally less desirable for routine initiation in very old or frail patients because they may lower heart rate, cause fatigue, and increase systolic pulse-wave amplitude. They remain appropriate when a compelling indication exists.

Vasodilating beta-blockers and direct vasodilators such as hydralazine and minoxidil are associated with increased orthostatic risk. Alpha-blockers are also less desirable because of their apparent association with orthostasis and falls in very old patients. Alpha-1 blockers, including doxazosin, prazosin, and terazosin, are particularly prone to causing orthostatic hypotension.

In older adults with heart failure, the therapeutic principles for reduced ejection fraction are generally the same as in younger patients, but altered pharmacokinetic and pharmacodynamic responses may require lower doses and more cautious titration. Blunted baroreceptor function and orthostatic dysregulation may prevent achievement of target doses of some neurohormonal antagonists.

Deprescribing and Ongoing Medication Review

Antihypertensive treatment should be reassessed when frailty progresses, SBP declines, orthostatic symptoms emerge, or new comorbidities or prescriptions alter the risk–benefit balance.

Medication review should identify:

• BP-lowering drugs that have become contraindicated

• Drugs that aggravate orthostatic hypotension

• Sedatives and prostate-specific alpha-blockers that may lower BP or increase fall risk

• Redundant or poorly tolerated treatment

• Treatment contributing to functional decline

ABPM may help identify orthostatic hypotension or highly variable BP, particularly when autonomic buffering is impaired. Deprescribing may be considered when BP falls with progressive frailty, but should be individualized and monitored.

Special Cardiovascular Contexts

Atrial Fibrillation

Hypertension in patients with atrial fibrillation is associated with higher risks of stroke, heart failure, major bleeding, and cardiovascular mortality. BP control should therefore form part of comprehensive atrial-fibrillation risk-factor management.

For most adults with atrial fibrillation, the treated SBP target is 120–129 mmHg when tolerated, with an on-treatment DBP ideally between 70 and 79 mmHg. When treatment is poorly tolerated, clinically significant frailty is present, or age is 85 years or older, a target below 140 mmHg or the lowest reasonably achievable level may be used.

ACE inhibitors or angiotensin receptor blockers may be more effective than some alternatives for preventing recurrent atrial fibrillation, although the comparative evidence described is limited.

Coronary Artery Disease and Older Adults

Older patients with coronary disease frequently have atypical symptoms rather than classic angina, and diagnosis may therefore be delayed. Treatment decisions are complicated by frailty, comorbidity, cognitive status, and increased vulnerability to bleeding, renal failure, and neurological complications. These factors should be incorporated into the overall BP strategy and not considered separately from the patient’s broader cardiovascular management.

Guideline-Based Recommendations

Follow-Up and Monitoring

Monitoring should focus on both BP values and clinical tolerance. Important outcomes to reassess include:

• Orthostatic symptoms

• Syncope or near-syncope

• Falls

• Fatigue

• Functional capacity

• Cognitive and mental status

• Ability to perform activities of daily living

• Medication adherence

• Polypharmacy

• Changes in frailty or life expectancy

BP measurement must be of high quality, particularly in very old and frail patients. ABPM or HBPM can assist with assessing BP variability, orthostatic hypotension, and the relationship between office and out-of-office measurements, although their treatment targets are extrapolated rather than derived from outcome-based trials.

Treatment should ordinarily be adjusted to achieve the intended target within 3 months, while avoiding rapid or poorly tolerated escalation. If treatment is tolerated, very old or frail patients should not automatically have effective therapy withdrawn. Conversely, progressive frailty, declining SBP, orthostatic hypotension, recurrent falls, or increasing treatment burden should prompt renewed assessment and possible deprescribing.

Prognosis and Overall Principles

Blood-pressure lowering in older adults can reduce the risk of major stroke, heart failure, and cardiovascular death, and current randomized evidence has not shown a clear loss of benefit among mildly frail trial participants. Nevertheless, evidence is less certain in people older than 80 years and in those with substantial frailty, because these groups have been underrepresented in trials.

The central therapeutic principle is individualized intensification. Fit, independent older adults should generally receive evidence-based treatment when it is tolerated. In very old, frail, cognitively impaired, functionally dependent, or orthostatic patients, treatment targets should reflect the balance between cardiovascular prevention and the risks of hypotension, syncope, falls, functional loss, and therapeutic burden. Quality of life, independence, and patient priorities are essential outcomes alongside BP control.